Recent Advances on the Role of Intensity–Modulated Radiotherapy in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 October 2024 | Viewed by 1422
Special Issue Editor
Special Issue Information
Dear Colleagues,
The emergence of intensity-modulated radiotherapy (IMRT) was one of the most revolutionary events in radiation oncology in the past 20 years. It enables the optimization of doses to tumors and the sparing of normal organs with information technology. These clinical superiorities were also demonstrated in many clinical trials for various diseases. Today, IMRT is widely accepted as curative or palliative treatment and gradually replacing conventional radiotherapy worldwide. In this IMRT era, new research fields such as hypofractionation, reirradiation, and palliative stereotactic radiotherapy have been developed. Information technology, artificial intelligence, and quality control/assurance came to be the main issues in this era.
Recently, proton therapy (PT) has emerged as the next generation following IMRT. PT has a physical characteristic known as the Bragg peak, where protons deposit most of their energy over a finite range without exit dose. Despite the edge, the optimal role of PT is not as well-defined as IMRT for now. It is partially caused by the lack of enough clinical evidence that PT is superior to IMRT. If you forecast the future, IMRT may be still the main tool for most radiation oncologists in the next decade.
In this Special Issue, we aim to elucidate the role of IMRT by reviewing the literature and reporting new findings addressing some of the unanswered questions.
Dr. Taro Murai
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Dr. Taro Murai
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- intensity modulated radiotherapy
- medical physics
- stereotactic radiotherapy
- proton therapy
- artificial intelligence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.